Genezen and Galibra Neuroscience Join Forces to Pioneer Gene Therapy for SSADH Deficiency

Genezen and Galibra Neuroscience: A Landmark Collaboration for Gene Therapy

In an exciting development for the field of gene therapy, Genezen, a specialized contract development and manufacturing organization (CDMO), has announced a partnership with Galibra Neuroscience, a pioneering biotechnology firm dedicated to addressing rare neurological disorders. This collaboration aims to advance Galibra's innovative gene therapy program for succinic semialdehyde dehydrogenase (SSADH) deficiency—a challenging condition that has long presented unmet medical needs.

The Challenge of SSADH Deficiency

SSADH deficiency is a rare and inherited disorder characterized by disrupted GABA metabolism stemming from mutations in the ALDH5A1 gene, responsible for producing the SSADH enzyme. Children afflicted by this condition face significant developmental delays, including impaired speech, low muscle tone, and behavioral challenges, with many experiencing seizures. Currently, there are no approved therapies that tackle the root causes of this complex disorder.

A Milestone in Research

The impetus behind this partnership stems from the personal journey of Brad and Carolyn Hoffman, who founded the SSADH Association in response to their son's diagnosis in 1998. Their efforts have led to substantial fundraising for research, enabling critical advancements such as natural history studies and the development of patient-derived stem cell lines. Furthermore, preclinical research into gene therapy conducted by prominent scientists, Drs. Alexander Rotenberg and Henry Lee, eventually led to the establishment of Galibra Neuroscience.

Galibra's GAL005 program represents a groundbreaking approach to treating SSADH deficiency by using an adeno-associated virus (AAV) gene therapy designed to deliver a functional copy of the ALDH5A1 gene via a novel capsid, referred to as CapX. This cutting-edge vehicle is engineered to effectively target human transferrin receptor 1, thus crossing the blood-brain barrier to deposit its therapeutic cargo directly into the central nervous system. Preclinical results have been promising, revealing that treated mice experienced restored survival rates and normalization of brain chemistry, as well as significant symptom alleviation.

Moving Towards Clinical Trials

As part of their partnership, Genezen will undertake the production of materials necessary for investigational new drug (IND)-enabling toxicology and biodistribution studies. Additionally, they will manufacture good manufacturing practice (cGMP) compliant clinical materials anticipated for the Phase 1 trial of Galibra's gene therapy. This step is crucial as it marks the transition from laboratory research to real-world applications that can benefit patients directly.

Geraldine D'Costa, Chief Technical and Commercial Officer at Genezen, expressed the company's commitment: "Our collaboration with Galibra is a significant step for us and the SSADH community. It underscores our dedication to ensuring that no delays hinder the progress of essential therapies."

Genezen emerged as Galibra's manufacturing partner following a thorough selection process, during which the quality of service, expertise in AAV technologies, and familiarity with rare diseases were highly regarded.

The Future of SSADH Treatment

Brad Hoffman, now the Director at Galibra Neuroscience, articulated the emotional drive behind their persistent pursuit of a gene therapy solution: "For nearly three decades, we have sought a viable treatment for SSADH deficiency. The remarkable preclinical results reaffirm our belief that gene therapy is the pathway to a cure. This partnership is a vital step toward delivering hope to families who have waited so long for a treatment."

In conclusion, as Genezen and Galibra Neuroscience embark on this important mission together, the future looks promising for SSADH deficiency patients. Their innovative strategies, combined with a focused determination, pave the way for potential breakthroughs in medical treatments that could dramatically improve lives. The collaboration not only marks advancements in gene therapy but signifies a beacon of hope for countless families navigating the challenges of genetic disorders.

About Genezen

Genezen takes pride in its status as a leading gene therapy CDMO, bringing over 12 years of experience and state-of-the-art facilities to the field. Their commitment to quality and innovation positions them as key partners in the global effort to deliver impactful gene and cell therapies.

About Galibra Neuroscience

Founded at Boston Children's Hospital by Drs. Rotenberg and Lee, Galibra Neuroscience champions the development of transformative therapies for rare neurological disorders. Their mission is defined by scientific innovation and active collaboration with patient communities, ensuring the advancement of programs that address the biological underpinnings of debilitating genetic conditions.